Lexaria, PegBio partner on GLP-1 drug delivery tech

Lexaria Biosciences said on Monday it had entered a partnership with PegBio to develop oral formulations of glucagon-like peptide-1 (GLP-1) drugs, a class widely used in treatments for obesity and diabetes.

Under the agreement, the companies will combine Lexaria’s DehydraTECH drug delivery platform with PegBio’s proprietary formulation technology to enhance the bioavailability and efficacy of GLP-1 therapies. The collaboration aims to create oral alternatives to injectable treatments, which currently dominate the market.

The move follows growing investor interest in GLP-1 drugs, driven by strong demand for weight-loss medications such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. Analysts have highlighted the potential for oral formulations to expand patient access and market penetration.

Lexaria’s shares were up 5% in morning trading, reflecting the market’s reaction to the partnership announcement. The company did not disclose financial terms of the deal.

PegBio, a China-based biotech firm, specializes in peptide-based therapies and has previously collaborated with global pharmaceutical companies on drug development projects. The partnership with Lexaria marks a strategic expansion into novel delivery technologies for GLP-1 drugs.

Industry observers noted that oral GLP-1 formulations could address key limitations of injectable treatments, including patient discomfort and adherence challenges. If successful, the collaboration could position both companies at the forefront of next-generation diabetes and obesity therapies.

Further details on timelines, clinical trials, and regulatory pathways were not provided in the announcement.